Stock Ratings / Health Care / VERU / dividends

SCYX (34) NSRX (36) GRDX (26) NNVC (33) ⌘ Pro Terminal →

Veru Inc. (VERU) Dividend Safety Gauge & 10-Year DRIP Compounder

$2.23 -1.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Veru Inc. (VERU) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $38.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VERU)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VERU)

✓Walkthrough of VERU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VERU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.89%🛡️ HOLDING TREND SUPPORT

2026-10-30O $2.25H $2.26L $2.16C $2.23VOL 78.9K

RES: $2.69SUP: $1.98SMA50: $2.46SMA200: $2.50

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VERU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VERU Butterfly Map → + Track VERU →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VERU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VERU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VERU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VERU)

Health Care Rank #555 of 1016 ⚔️ SCYX vs VERU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VERU vs. SCYX, NSRX, GRDX, NNVC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Veru Inc. (VERU) ranks #555 by composite RQD confidence (43/100, grade D-) and #781 by equity capitalization ($38.0M). Within this direct 5-issuer industry benchmark cohort, VERU leads on earnings valuation at N/A trailing P/E, while GRDX leads on capital efficiency and profitability with -20.0% ROIC and -30.0% gross margin. VERU currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VERU ACTIVE Veru Inc.	D-	43/100	—	—	-35.0%	-1.76%	$38.0M	Benchmark Subject
SCYX SCYNEXIS Inc.	E	34/100	—	—	-35.0%	-2.28%	$38.4M	/scyx-vs-veru →
NSRX Nasus Pharma Ltd.	D-	36/100	—	—	-35.0%	-4.49%	$37.4M	/nsrx-vs-veru →
GRDX GridAI Technologies Corp.	E	26/100	—	-30.0%	-20.0%	-5.38%	$38.9M	/grdx-vs-veru →
NNVC NanoViricides Inc.	E	33/100	—	—	-35.0%	-1.38%	$36.5M	/nnvc-vs-veru →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0000863894

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Veru Inc. (VERU) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $16.9M , and -100.0% cumulative change since FY2023) , GAAP net income of -$22.7M, operating cash flow of -$30.0M, and free cash flow of -$30.0M (-37.6% YoY). On the balance sheet, VERU closed FY2025 with $47.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$0	-$22.7M	-$30.0M	-$30.0M	$47.6M	—
FY2024 (FY)	2024-09-30	$16.9M	-$37.8M	-$21.7M	-$21.8M	$39.8M	—
FY2023 (FY)	2023-09-30	$16.3M	-$93.2M	-$88.0M	-$88.0M	—	—

3. VERU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VERU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Veru Inc. (NASDAQ: VERU) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $2.23 (-1.76% 1D, market cap $38.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, VERU ranks #555 in composite RQD confidence.

How does VERU compare to SCYX and NSRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VERU carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SCYX (SCYNEXIS Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $38.4M) and NSRX (Nasus Pharma Ltd.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $37.4M). Among the 5-stock peer group, VERU leads on earnings multiple (N/A) while GRDX leads on capital efficiency (-20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VERU?

Per VERU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000863894), Veru Inc. generated $0 in revenue (-100.0% YoY), -$22.7M in net income, and -$30.0M in free cash flow against $47.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VERU trading relative to its 50-day, 200-day, and 52-week technical levels?

VERU last traded at $2.23 (-1.76% on volume of 56,944 shares), positioning the stock -9.35% below its 50-day simple moving average ($2.46) and -10.80% below its 200-day simple moving average ($2.50). Across its 52-week range of $2.05 to $7.33, VERU sits at the 3.4% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.95 to $2.51).

VERU Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does VERU pay a dividend and is it safe?

Veru Inc. (VERU) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: VERU RQD Cockpit VERU 12M Forecast VERU Earnings & Move VERU Dividends & DRIP VERU Insiders & 13F VERU Whale Options VERU Profit Sankey VERU News & Why